89.64
2.64 (3.03%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Abivax SA | 混合的 | 看涨 |
AIStockmoo 评分
| 价值 35% | -4.2 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -4.2 |
| 时机 35% | 0.3 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | -0.5 |
| 技术平均移动指标 参考 | 1.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.21 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -22.5% |
| 支柱一致性 | ×1.18 |
| 不计入评分 | |
| 价格波动 参考 | 5.0 |
| 最终评分 | -1.96 |
|
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Growth |
| 机构持股比例 | 50.19% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Darwin Global Management, Ltd. | 30 Jun 2026 | 3,621,583 |
| Helikon Investments Ltd | 30 Jun 2026 | 2,787,131 |
该时间范围内无数据。
该时间范围内无数据。
投资组合